Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: Lesion detectability and dosimetric projections for 90Y radioimmunotherapy

Journal of Nuclear Medicine

Volumn 49, Issue 7, 2008, Pages 1066-1074

  Pandit Taskar, Neeta ^a,b   O'Donoghue, Joseph A ^a   Morris, Michael J ^a,b   Wills, Eze A ^b   Schwartz, Lawrence H ^a   Gonen, Mithat ^a   Scher, Howard I ^a,b   Larson, Steven M ^a,b   Divgi, Chaitanya R ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Dosimetry; J591 antibody; Prostate cancer; Radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; INDIUM 111; MONOCLONAL ANTIBODY J591; YTTRIUM 90;

ARTICLE; BONE LESION; CASTRATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG UPTAKE; HUMAN; IMAGE ANALYSIS; ISOTOPE LABELING; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIOIMMUNOTHERAPY; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WHOLE BODY IMAGING;

ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; BONE NEOPLASMS; FEASIBILITY STUDIES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; INDIUM RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; ORCHIECTOMY; PILOT PROJECTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 46749104779     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.049502     Document Type: Article

References (22)

1. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer. 1998;83:2259-2269.
2. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637-640.
3. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85.
4. Rosenthal SA, Haseman MK, Polascik TJ. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol. 2001;7:27-37.
5. Petronis JD, Regan F, Lin K. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med. 1998;23:672-677.
6. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000;60:5237-5243.
7. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol. 2003;30:667-676.
8. Hamilton A, King S, Liu H, Moy P, Bander N, Carr F. A novel humanized antibody against prostate specific membrane antigen (PSMA) for in vivo targeting and therapy [abstract]. Proc Am Assoc Cancer Res. 1998;39:440.
9. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med. 2003;44:610-617.
10. Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol. 2003;170:1717-1721.
11. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57:3629-3634.
12. Nanus DM, Milowsky MI, Kostakoglu L, et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol. 2003;170(suppl):S84-S89.
13. 177Lu? J Nucl Med. 2005;46:634-641.
14. 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591-4601.
15. Morris MJ, Divgi CR, Pandit-Taskar N, et al. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res. 2005;11:7454-7461.
16. Morris MJ, Pandit-Taskar N, Divgi CR, et al. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res. 2007;13:2707-2713.
17. Barrett PH, Bell BM, Cobelli C, et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47:484-492.
18. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
19. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694.
20. Bardiès M, Chatal JF. Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta-dosimetry of small spheres. Phys Med Biol. 1994;39:961-981.
21. Gonen M, Panageas KS, Larson SM. Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology. 2001;221:763-767.
22. O'Donoghue JA, Baidoo N, Deland D, Welt S, Divgi CR, Sgouros G. Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy. Cancer Biother Radiopharm. 2002;17:435-443.